...EPIGENETIX2, was selected for funding in the second phase of the French Worldwide Innovation Challenge. Hybrigenics... ...of the French Worldwide Innovation Challenge. PicoSeq will be responsible for SIMDEQ’s global commercialization. PicoSeq, Hybrigenics... ...to provide further details, and Bpifrance could not be reached. PicoSeq S.A.S. , Paris, France Hybrigenics...
...by one year its 2011 deal with Servier to identify compounds against deubiquitinating enzyme targets. Hybrigenics... ...€920,000 ($1 million) for the extension (see BioCentury, Oct. 17, 2011 & Feb. 3, 2014). Hybrigenics...
Hybrigenics S.A. (Euronext:ALHYG), Paris, France Business: Cancer, Proteomics, Supply/Service Date completed: 2014-10-22 Type: Private placement Raised: EUR4.6 million ($5.9 million) Shares: 3.5 million Price: EUR1.32 Shares after offering: 29.4 million Investor: Crede Capital Group
WIR...
...FDA granted Orphan Drug designation to inecalcitol from Hybrigenics to treat chronic lymphocytic leukemia (CLL). The... ...CLL. Hybrigenics has exclusive, worldwide rights to inecalcitol from Merck (see BioCentury, Feb. 13, 2006). Hybrigenics...
...EPIGENETIX2, was selected for funding in the second phase of the French Worldwide Innovation Challenge. Hybrigenics... ...of the French Worldwide Innovation Challenge. PicoSeq will be responsible for SIMDEQ’s global commercialization. PicoSeq, Hybrigenics... ...to provide further details, and Bpifrance could not be reached. PicoSeq S.A.S. , Paris, France Hybrigenics...
...by one year its 2011 deal with Servier to identify compounds against deubiquitinating enzyme targets. Hybrigenics... ...€920,000 ($1 million) for the extension (see BioCentury, Oct. 17, 2011 & Feb. 3, 2014). Hybrigenics...
Hybrigenics S.A. (Euronext:ALHYG), Paris, France Business: Cancer, Proteomics, Supply/Service Date completed: 2014-10-22 Type: Private placement Raised: EUR4.6 million ($5.9 million) Shares: 3.5 million Price: EUR1.32 Shares after offering: 29.4 million Investor: Crede Capital Group
WIR...
...FDA granted Orphan Drug designation to inecalcitol from Hybrigenics to treat chronic lymphocytic leukemia (CLL). The... ...CLL. Hybrigenics has exclusive, worldwide rights to inecalcitol from Merck (see BioCentury, Feb. 13, 2006). Hybrigenics...
